SGMS1: A Protein Involved in P27 and NF-kappa-B Regulation (G259230)

Target Name: SGMS1

NCBI ID: G259230

SGMS1

SGMS1: A Protein Involved in P27 and NF-kappa-B Regulation

SGMS1 (hmob33) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the heat shock protein (HSP) family, which are proteins that are expressed in high levels in response to environmental stressors, such as heat, cold, and exercise.

One of the unique features of SGMS1 is its ability to interact with other proteins, particularly the protein known as p27. P27 is a well-known protein that is involved in the regulation of cell growth, differentiation, and survival. It is often expressed in high levels in response to stress, and it has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

SGMS1 has been shown to play a role in the regulation of p27 expression and activity. It has been shown to physically interact with p27, and to regulate its stability and localization to the endoplasmic reticulum. This suggests that SGMS1 may be a useful drug target or biomarker for the treatment of diseases associated with p27 dysfunction.

In addition to its role in regulating p27 expression, SGMS1 has also been shown to be involved in the regulation of a number of other proteins, including the transcription factor NF-kappa-B. NF-kappa-B is a well-known protein that is involved in the regulation of a wide range of cellular processes, including inflammation, stress response, and metabolism.

SGMS1 has been shown to play a role in the regulation of NF-kappa-B activity, by physically interacting with its downstream target, the protein known as nuclear factor of activated T cells (NFAT). This suggests that SGMS1 may be a useful drug target or biomarker for the treatment of diseases associated with NF-kappa-B dysfunction.

In conclusion, SGMS1 is a protein that has been shown to play a number of important roles in the regulation of cellular processes, including the regulation of p27 expression and activity, as well as the regulation of NF-kappa-B activity. These findings suggest that SGMS1 may be a useful drug target or biomarker for the treatment of diseases associated with these processes. Further research is needed to fully understand the role of SGMS1 in disease, and to develop effective treatments.

Protein Name: Sphingomyelin Synthase 1

Functions: Major sphingomyelin synthase at the Golgi apparatus (PubMed:17449912, PubMed:14685263). Catalyzes the reversible transfer of phosphocholine moiety in sphingomyelin biosynthesis: in the forward reaction transfers phosphocholine head group of phosphatidylcholine (PC) on to ceramide (CER) to form ceramide phosphocholine (sphingomyelin, SM) and diacylglycerol (DAG) as by-product, and in the reverse reaction transfers phosphocholine from SM to DAG to form PC and CER. The direction of the reaction depends on the levels of CER and DAG in Golgi membranes (PubMed:14685263, PubMed:17449912, PubMed:14976195, PubMed:17982138, PubMed:19454763). Does not use free phosphorylcholine or CDP-choline as donor (PubMed:14976195, PubMed:14685263). Regulates receptor-mediated signal transduction via mitogenic DAG and proapoptotic CER, as well as via SM, a structural component of membrane rafts that serve as platforms for signal transduction and protein sorting (PubMed:14976195, PubMed:17449912, PubMed:17982138). Plays a role in secretory transport via regulation of DAG pool at the Golgi apparatus and its downstream effects on PRKD1 (PubMed:18370930, PubMed:21980337)

The "SGMS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SGMS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets